Introduction
Aspartate aminotransferase (AspAT, EC 2.6.1.1) is present as two homologous, genetically independent isozymes in animal cells, one located in the cytoplasm (cAspAT) and the other in mitochondria (mAspAT) (1, 2) . mAspAT was recognized as a moonlighting enzyme because it was found to have two or more different functions. Similar to cAspAT, mAspAT catalyzes the reversible reaction of L-aspartate and α-ketoglutarate (α-KG) into oxaloacetate and L-glutamate via a pingpong mechanism, with pyridoxal 5'-phosphate (PLP) as an essential cofactor (3). Glutamine not only provides a carbon source to fuel the tricarboxylic acid (TCA) cycle via α-KG, but also provides nitrogen for the synthesis of nonessential amino acids and nucleotides, i.e., purines, pyrimidines, alanine, serine, aspartate, ornithine, glycine, cysteine, arginine, asparagine, and proline (4, 5) . Therefore, mAspAT is one of the key enzymes that links amino acid metabolism to carbohydrate metabolism through catalysis of the reversible transamination reaction.
Different to cAspAT, mammalian mAspAT is also recognized as kynurenine aminotransferase-IV because this enzyme is capable of catalyzing the irreversible transamination of kynurenine to produce kynurenic acid (KYNA) and plays a role in the biosynthesis of KYNA in rat, mouse and human brains (6) (7) (8) . KYNA is an endogenous antagonist of N-methyl-D-aspartate and α7-nicotinic acetylcholine receptors (9, 10) . In addition, KYNA is identified as an endogenous ligand for an orphan G-protein-coupled receptor (11) . Abnormal concentration of KYNA in brain tissue has been observed in patients with mental and neurological disorders, including the Huntington's disease, Alzheimer's disease, and schizophrenia (12) . Therefore, mAspAT can be envisioned to be a valid molecular target for the treatment of these neurological diseases.
Additionally, mAspAT is recognized as plasma membrane fatty acid binding protein (FABPpm) because this enzyme has a high affinity for long-chain fatty acids (LCFA) and is a key enzyme involved in the transport of the saturated LCFA and unsaturated LCFA (13, 14) . Accordingly, it is important to study the structure-function relationships of mAspAT protein because it possesses both enzymatic catalytic activity and LCFA binding activity. To date, AspATs have been purified from many sources and X-ray structures have been determined for those from Escherichia coli (15) , cytosolic yeast cytoplasm (16) , pig cytoplasm (17) , chicken mitochondria (18) , and chicken cytoplasm (19) . However, the crystal structure of the human mAspAT has not been solved.
Human mAspAT contains 4 cysteine residues forming two disulfide bonds. In addition, the overexpression of mAspAT is toxic to the growth of host cells as mAspAT is a key metabolic enzyme in amino acid metabolism. This study aimed to generate and purify recombinant human mAspAT protein in a high level that is sufficient for characterization analysis and further structural studies. We report here the expression, purification and characterization of human mAspAT expression in E. coli periplasmic space using the plasmid pET-22b. Moreover, the crystallization and preliminary X-ray analysis of mAspAT protein were also performed.
Materials and Methods

Materials
The pET-22b (+) vector and E. coli strain BL21 (DE3) were obtained from Novagen (Beijing, China). pMD18-T Simple Vector, E. coli strain JM 109, T4 DNA ligase, Ex Taq DNA polymerase, Noc I and Xho I restriction enzymes were purchased from Takara Biotechnology (Dalian, China). The Amicon Ultra centrifugal filter (3 kDa) used for filtration of the cell culture medium was obtained from Millipore Corporation (Bedford, MA, USA). The AST (SGOT) Reagent Kit used for monitoring the activity of mAspAT was purchased from BIO QUANT (San Diego, CA, USA). Crystallization Screening kits were purchased from Hampton Research (Oklahoma City, OK, USA). All primers were synthesized by Takara Biotechnology.
Construct of expression vector
The nucleotide sequence encoding for the mature form of human mAspAT (GenBank accession no. M22632.1) was artificially synthesized by Taihe Biotechnology Co., Ltd. (Beijing, China). Nco I and Xho I restriction sites were added to the N-terminus and C-terminus of the mAspAT sequence by PCR, respectively, using the forward primer F1 5'-CATGCCATGGCAGAGCCAG CTCCTGGTGGA-3' (Nco I site is underlined) and the reverse primer R1 5'-CCGCTCGAGCTTGGTGACCT GGTGAATGGCAT-3' (Xho I is underlined). The PCR product was digested with Nco I-Xho I, and cloned into the Nco I-Xho I site of the pMD18-T simple vector and then transformed into E. coli strain JM 109. Nucleic acid sequences of the cloning DNA fragment were confirmed by DNA sequencing (BigDye™ Kit, Applied Biosystems, USA) and ABI PRISM™ 3730XL DNA Analyzer, according to the recommended protocols. The target DNA fragment was further subcloned in the same site of pET-22b (+) vector, resulting in pET22b-hmAspAT. The resulting vector was then transformed into chemically competent E. coli strain BL21 (DE3) by heat shock for protein expression.
Expression of human mAspAT
The single colony of E. coli BL21 (DE3) harboring the expression vector in 30 mL of Luria-Bertani (LB) medium containing 100 μg/mL ampicillin, and then cultivated at 37ºC until the optical density (OD 600 ) reached 0.6. The cells were harvested by centrifugation at 4,000 × g for 10 min, and resuspended in 3 L fresh LB medium containing 100 μg/mL ampicillin. Subsequently, protein expression was induced with 1 mM isopropyl β-ᴅ-1-thiogalactopyranoside (IPTG) for 20 h at 16ºC. The cells were harvested by centrifugation at 8,000 × g for 15 min and washed with buffer A (20 mM NaH 2 PO 4 , 0.5 M NaCl, pH 7.4). Approximated 45 g (wet weight) cells were obtained from 3 L culture. After centrifugation, the cell pellets was resuspended in 40 mL (for 1 L culture) ice-cold extraction buffer A, and lysed by ultrasonication at ice-cold temperature using an UP400S instrument (Dr. Hielscher GmbH, Stuttgart, Germany). The cell lysis was centrifuged at 12,000 rpm for 15 min to separate soluble (supernatant) and precipitated (pellet) fractions.
Purification of human mAspAT
The resulting supernatant was filtered with a 0.22 μm syringe filter and then loaded onto a 5 mL HisTrap TM FF crude column (GE Healthcare, Uppsala, Sweden) pre-equilibrated with buffer A. After washing the column with buffer A containing 50 mM imidazole, the target protein was eluted with buffer B (20 mM NaH 2 PO 4 , 0.5 M NaCl, 300 mM imidazole, pH 7.4). The buffer was exchanged with 20 mM Tris buffer (pH 7.5) containing 20 mM NaCl using a 5 mL HiTrap TM desalting column (GE Healthcare). The desalted sample was loaded onto a 1 mL SP Sepharose TM FF column (GE Healthcare). After washing, the column were then flash-cooled in liquid nitrogen. All X-ray diffraction data were collected on the ESRF beamline BL-17U at the Shanghai Synchrotron Radiation Facility in China and were processed using the HKL-2000 package (20) . Diffraction data were collected at a wavelength of 0.98 Å, an oscillation angle of 1º, an exposure time of 1 s per image and a crystal-to-detector distance of 250 mm.
Results and Discussion
Human mAspAT is encoded by nuclear gene and synthesized in the cytoplasm as precursor protein containing N-terminal presequences of 30 amino acid residues in length (21) . After completion of translation, human mAspAT is imported into mitochondria matrix via several apparently discrete steps including proteolytic cleavage of the presequence with processing proteases and assembly into mature protein (22, 23) . Therefore, the mature form of human is posttranslationally imported into the mitochondrial matrix and lack 30 amino acid residues from the N-terminus compared with the precursor (24) . The recombinant expression results indicated that the precursor form of mAspAT was found to express as inclusion body in E. coli expression system, however, the mature could be found in the supernatant of the bacterial homogenate (25) . Therefore the mature form of human mAspAT was chosen to study the recombinant expression and crystallization of protein.
Human mAspAT is a toxic protein to host cell and also contains 4 cysteine residues forming two disulphide bonds. In order to obtain the large amounts of soluble mature mAspAT in E. coli for the crystallization study, we introduced the use of pET-22b plasmid as the expression vector. The pET-22b vector possessed an N-terminal pelB secretion signal under the control of the strong bacteriophage T7 promoter, which directed the recombinant protein to the E. coli periplasmic space (26) . The periplasm of E. coli contains the disulfide oxidoreductases and isomerases, which is an oxidizing environment and can facilitate formation of disulfide bonds that are always required for correct protein folding (27, 28) . Therefore the periplasm of E. coli was expected to be an ideal compartment for expression of human mAspAT.
The plasmid pET22b-hmAspAT was then transformed into E. coli BL21 (DE3). When the culture was propagated at 37°C until OD 600 reached 0.6, the expression of the fusion protein was induced with 1.0 mM of IPTG, and then the culture was grown for an additional 20 h at 16°C. After lysis, the supernatant was analyzed by Western blotting using anti-his tag mouse antibody. Western blot analysis confirmed that the recombinant human mAspAT was present in the soluble fraction of the cell lysate after induction with IPTG ( Figure 1A ).
was eluted with a linear gradient of NaCl from 20 to 500 mM in Tris buffer (pH 7.5) at a flow rate of 1 mL/ min. Fractions with enzyme activity were pooled and the buffer was exchanged for 20 mM Tris (pH 7.0) containing 20 mM NaCl by using a 5 mL HiTrap TM desalting column (GE Healthcare), and then the protein was concentrated to a final concentration of 5 mg/mL with a 3 kDa cut-off concentrator (Millipore). During purification, the activity of mAspAT was monitored using the AST (SGOT) Reagent Kit (BQ Kits). In this method, a diazonium salt was used which selectively reacted with the oxalacetate to produce a color complex that was measured photometrically. According to the protocol, reaction mixture including enzyme, substrate, assay buffer and assay developer was incubated at 37°C for 60 min, and OD 450 was then measured. One unit of enzyme is defined as the amount of enzyme which generates 1.0 μmol of glutamate per minute at 37°C. The purity of the eluted protein was analyzed by SDS-PAGE and found to be > 95%.
SDS-PAGE and Western blot analysis
SDS-PAGE analysis was performed using 12% resolving gel and 5% stacking gel. The protein bands were visualized by Coomassie brilliant blue R-250 and then analyzed by image-density analysis software (GelPro, USA). Soluble fractions of cell lysates after IPTG induction were subjected to SDS-PAGE and transferred to polyvinylidene difluoridemembrane (Millipore). The membranes were blocked with 5% defatted milk at room temperature for 60 min and then incubated with anti-his tag mouse monoclonal antibody (1 μg/ mL, Millipore) at 4ºC overnight. The membranes were washed twice with PBS buffer and incubated with horseradish peroxidase conjugated goat anti-mouse IgG (1:5,000, Millipore) at room temperature for 90 min. Finally, the membranes were washed five times with PBS buffer, and a 3′-diaminobenzidine kit was used for color development (Sigma-Aldrich, St. Louis, Mo, USA).
Crystallization and X-ray diffraction of human mAspAT
Initial crystallization screening was carried out in 24-well tissue-culture plates at 277 K by the hanging-drop vapor diffusion method using commercially available Index Screen, Crystal Screen, Crystal Screen 2 and PEG/Ion Screen (Hampton Research). Crystals were grown in a mixture containing 1 μL of protein (5 mg/ mL in 20 mM Tris pH 7.0, 20 mM NaCl) and 1 μL of reservoir solution and were equilibrated against 400 μL reservoir solution. Crystallization conditions were optimized based on the initial screening.
Single crystals were soaked for several minutes in a reservoir solution containing 25%(v/v) glycerol and Recombinant human mAspAT was purified by a combination of immobilized metal-affinity chromatography and cation exchange chromatography. The purified protein was resolved as a single band in the SDS-PAGE gel with a molecular mass of about 43 kDa, indicating that these two chromatographic steps were very effective ( Figure 1B, lane 3) . The final yield of pure protein was approximately 10 mg from 1 L of expression culture, allowing the preparation of approximately 2 mL of a 5.0 mg/mL protein sample for crystallization assays. After two chromatography steps, the specific activity and overall recovery of purified mAspAT were 36.3 U/mg and 19.4%, respectively ( Table 1 ). The purification of mAspAT protein is summarized in Table 1 .
The optimal pH for enzyme activity was determined to be pH 8.5 (Figure 2A ), similar to that (pH 8.0) of AspAT from Bacillus subtilis (29) . Actually, the enzyme activity over the pH range 8.0-10.0 was more than 60% of the maximum activity (Figure 2A) . Moreover, human mAspAT showed optimal activity at 47.5°C and maintained over 80% activity at temperatures from 40 to 60°C, indicating a certain degree of thermostability in this temperature range ( Figure 2B ). The recombinant human mAspAT tended to have relatively high activity and stability in alkaline environments, similar to that of the AspATs from B. subtilis and B. circulans (29, 30) . Thus the recombinant human mAspAT had optimal Figure 3A) .
The human mAspAT crystal data were collected to a resolution of 2.99 Å ( Figure 3B ) and processed using the HKL-2000 package (20) . The crystals belonged to the space group P1, with unit cell parameters a =56.7, b = 76.1, c = 94.2 Å, α =78.0, β =85.6, and γ =78.4º. The space group of cytosolic AspATs from chicken (19) , pig heart (17), and Saccharomyces cerevisiae (16) is P2 1 2 1 2 1 , while the space group for AspAT crystals from E. coli is P2 1 (15) . Data collection statistics are summarized in Table 2 .
In conclusion, we constructed the expression construct for human mAspAT and expressed it as an active enzyme in E. coli periplasmic space. Moreover, the recombinant human mAspAT was purified and its some biochemical properties were also examined. The crystals of mAspAT protein have been obtained by the hanging-drop vapor-diffusion method and an X-ray diffraction data set was collected from a single crystal to 2.99 Å resolution. This study may provide a method useful for the recombinant preparation of other cytotoxic proteins. The structure of mAspAT protein will provide insight into the structure reactivity relationships of human mAspAT and its substrates. The human mAspAT structure will be useful for screening of its inhibitors and may also have implications for future therapeutic approaches. 
